Skip to main content
SpringerLink
Log in

Management of Heart Failure

  • Chapter
Cardiac Drug Therapy

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1160 Accesses

Abstract

Heart failure (HF), unlike coronary heart disease (CHD), has no territorial boundaries.

  • The world faces an epidemic of heart failure. The plague of HF is common in developed and in developing countries.

  • Although treatment strategies have improved considerably over the past decade, improvement in outcomes remain modest and the incidence of HF is increasing. Some of this increase is owing to an aging population in all countries.

  • In the United States about 5 million individuals have HF. In addition, more than half a million patients are diagnosed with a first episode of HF each year, and approximately 80% of these are over age 65.

  • In the United States, HF causes more than 300,000 deaths annually (1) over the past 10 yr hospitalizations for HF have risen from approx 550,000 to approx 900,000 (2). The cost worldwide is astronomic: in the United States more Medicare dollars are spent on the management of HF than for any other diagnosis (3) and this cost is estimated to be $28 billion annually.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. O’Connell JB, Bristow M. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1999;13:S107.

    Google Scholar 

  2. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey. Am Heart J 1999; 137:352.

    Article  PubMed  CAS  Google Scholar 

  3. Hunt SH, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2001;38:2101.

    Article  PubMed  CAS  Google Scholar 

  4. Hunt S A, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46: 1116–1143.

    Article  Google Scholar 

  5. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-typenatriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161.

    Article  PubMed  CAS  Google Scholar 

  6. Wilson Tang WH, Francis GS. The year in heart failure. J Am Coll Cardiol 2005;46:2125–2133.

    Article  Google Scholar 

  7. Packer M. Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure?: The price we pay for interfering with evolution. J Am Coll Cardiol 1985;6:171.

    Google Scholar 

  8. Packer M, Lee WH, Yushak M, et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847.

    Article  PubMed  CAS  Google Scholar 

  9. CONSENSUS: Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 1987;316:1429.

    Article  Google Scholar 

  10. A-HeFT: Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.

    Article  PubMed  CAS  Google Scholar 

  11. Cohn JN, Archibald DG, Francis GS, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: Influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987;75(JV):IV–49.

    Google Scholar 

  12. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314: 1547.

    Article  PubMed  CAS  Google Scholar 

  13. V-HeFTII: Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303.

    Article  PubMed  CAS  Google Scholar 

  14. SOLVD Investigators. Effect of enalapril on survival in patients with reduced ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293.

    Article  Google Scholar 

  15. Furberg CD, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol 1985;55:1110.

    Article  PubMed  CAS  Google Scholar 

  16. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. Am J Cardiol 1988;62:41A.

    Article  PubMed  CAS  Google Scholar 

  17. Agostoni PG, De Gasare N, Doria E, et al. Afterload reduction: A comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J 1986;55:391.

    Article  PubMed  CAS  Google Scholar 

  18. SAVE: Pfeffer MA, Braunwald E, Moye LA, et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669.

    Article  PubMed  CAS  Google Scholar 

  19. AIRE: Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821.

    Google Scholar 

  20. Cleland JGF, Dargie HJ, Mc Alpine H, et al. Severe hypotension after first dose of enalapril in heart failure. BMJ 1985;291:1309.

    Article  PubMed  CAS  Google Scholar 

  21. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: Amulticenter study. J Am Coll Cardiol 2000;36:2090.

    Article  PubMed  CAS  Google Scholar 

  22. ATLAS Study Group. Packer M, Poole-Wilson PA, Armstrong P, et al. Comparative effects of low and high doses of angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312.

    PubMed  CAS  Google Scholar 

  23. CHARM: Granger CB, McMurray JJV, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors; the CHARM-alternative trial. Lancet 2003;362: 772–776.

    Article  PubMed  CAS  Google Scholar 

  24. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  25. Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 1981;64:499.

    PubMed  CAS  Google Scholar 

  26. PRAISE: Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. For the Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107.

    Article  PubMed  CAS  Google Scholar 

  27. Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;336:29.

    Article  Google Scholar 

  28. RALES: Pitt B, Zannad F, Remme WJ, et al. for the Randomized Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709.

    Article  PubMed  CAS  Google Scholar 

  29. Stevens LA, Coresh J, Green T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.

    Article  PubMed  CAS  Google Scholar 

  30. Hass GJ, Abraham WT. The challenge of heart failure. J Am Coll Cardiol 2005;46:2052–2053.

    Article  Google Scholar 

  31. Khan M Gabriel, Goodwin JF. Cardiomyopathy. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.

    Google Scholar 

  32. Bristow MR, Kantrowitz NE, Ginsburg R, et al. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985;17:41.

    Article  PubMed  CAS  Google Scholar 

  33. Waagstein F, Hjalmarson A, Swedberg K, et al. Beta-blockers in dilated cardiomyopathies: They work. Eur Heart J 1993;173(Suppl A).

    Google Scholar 

  34. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349.

    Article  PubMed  CAS  Google Scholar 

  35. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. Lancet 2001;357:1385.

    Article  Google Scholar 

  36. Packer M, Coats JS, Fowler MB, et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651.

    Article  PubMed  CAS  Google Scholar 

  37. Waagstein F, Bristow MR, Swedberg K, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342:1441.

    Article  PubMed  CAS  Google Scholar 

  38. MERIT/HF: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 2000;283:1295.

    Article  Google Scholar 

  39. CIBIS-II: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). Arandomized trial. Lancet 1999;353: 9–13.

    Article  Google Scholar 

  40. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525.

    Article  Google Scholar 

  41. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.

    Article  PubMed  CAS  Google Scholar 

  42. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980;303:1443.

    Article  PubMed  CAS  Google Scholar 

  43. Gheorghiade M, St Clair J, St Clair C, et al. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987;9:849.

    PubMed  CAS  Google Scholar 

  44. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: Placebocontrolled trial in outpatients. BMJ 1977;1:749.

    PubMed  CAS  Google Scholar 

  45. Packer M, Gheorghiade M, Young JB, et al. for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993;329:1.

    Article  PubMed  CAS  Google Scholar 

  46. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A.

    Article  Google Scholar 

  47. Schenck-Gustafsson K, Jublin-Dannfelt A, Dahlquist R. Renal function and digoxin clearance during quinidine therapy. Clin Physiol 1982;2:401.

    PubMed  CAS  Google Scholar 

  48. Zatuchni J. Verapamil-digoxin interaction. Am Heart J 1984;108:412.

    Article  PubMed  CAS  Google Scholar 

  49. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol 1985;5: 82A.

    Article  PubMed  CAS  Google Scholar 

  50. Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Circulation 1990;82:1744.

    Google Scholar 

  51. Mikulic E, Cohn JN, Franciosa JA. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circulation 1977;56:528.

    PubMed  CAS  Google Scholar 

  52. Little WC. Enhanced load dependence of relaxation in heart failure: Clinical implications. Circulation 1992;85:2326.

    PubMed  CAS  Google Scholar 

  53. Little WC, Cheng CP. Diastolic dysfunction. Cardiol Rev 1998;6:231.

    Article  PubMed  Google Scholar 

  54. Meier-Ewert HK, Gaasch WH. What is diastolic heart failure and how do we treat it? ACC Curr J Rev Nov/Dec:52, 2001.

    Google Scholar 

Suggested Reading

  • Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.

    Article  PubMed  CAS  Google Scholar 

  • Bhatia RS, Tu JV, Lee DS. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260–269.

    Article  PubMed  CAS  Google Scholar 

  • Davis BR, Piller LB, Cutler JA, et al. for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006;113:2201–2210.

    Article  PubMed  CAS  Google Scholar 

  • de Goma EM, Vagelos RH, Fowler MB. Emerging therapies for the management of decompensated heart failure. J Am Coll Cardiol 2006;48:2397–2409.

    Article  CAS  Google Scholar 

  • Gheorghiade M, Dirk J. van Veldhuisen, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556–2564.

    Article  PubMed  Google Scholar 

  • Greenberg B, Mehra MR. All patients with heart failure and intraventricular conduction defect or dyssynchrony should not receive cardiac resynchronization therapy. Circulation 2006;114:2685–2691.

    Article  PubMed  Google Scholar 

  • Hass GJ, Abraham WT. The challenge of heart failure. J Am Coll Cardiol 2005;46:2052–2053.

    Article  Google Scholar 

  • Jhund P, McMurray JV. Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor?: Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 2006;113:2566–2568.

    Article  PubMed  Google Scholar 

  • Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485–2489.

    Article  PubMed  Google Scholar 

  • Owan TE, Hodge DO, Herges RM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.

    Article  PubMed  CAS  Google Scholar 

  • Pfeffer MA. Editorial Comment. Blood pressure in heart failure: A love-hate relationship. J Am Coll Cardiol 2007;49:40–42.

    Article  PubMed  Google Scholar 

  • Ramasubbu K, Mann DL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2006; 47:342–344.

    Article  PubMed  Google Scholar 

  • Remme WJ, Torp-Pedersen C, Cleland JGF, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: research from COMET. J Am Coll Cardiol 2007;49:963–971.

    Article  PubMed  CAS  Google Scholar 

  • Scirica BM, Morrow DA, Cannon CP, et al. for the PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 STUDY. J Am Coll Cardiol 2006;47:2326–2331.

    Article  PubMed  CAS  Google Scholar 

  • Stevens LA, Coresh J, Greene T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.

    Article  PubMed  CAS  Google Scholar 

  • Takemoto Y, Hozumi T, Sugioka K, et al. Beta-blocker therapy induces ventricular resynchronization in dilated cardiomyopathy with Narrow QRS complex. J Am Coll Cardiol 2007;49:778–783.

    Article  PubMed  CAS  Google Scholar 

  • Tang WH, Francis GS. The year in heart failure. J Am Coll Cardiol 2006;48:2575–2583.

    Article  PubMed  Google Scholar 

  • Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

(2007). Management of Heart Failure. In: Cardiac Drug Therapy. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-238-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-238-0_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-904-8

  • Online ISBN: 978-1-59745-238-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation